Case	O
Presentation	O

The	O
patient	O
is	O
an	O
80	O
year	O
old	O
male	O
with	O
diabetes	O
mellitus	O
and	O
hypertension	O
,	O
who	O
at	O
age	O
74	O
(	O
March	O
2001	O
)	O
had	O
received	O
a	O
living	O
non	O
-	O
related	O
donor	O
kidney	B-Organ
transplant	O
.	O

At	O
that	O
time	O
he	O
was	O
discharged	O
with	O
a	O
double	O
immunosuppressive	O
therapy	O
consisting	O
of	O
prednisone	O
20	O
mg	O
/	O
day	O
and	O
mophetil	O
mycophenolate	O
1	O
.	O
5	O
gr	O
/	O
day	O
.	O

No	O
calcineurin	O
inhibitor	O
was	O
administered	O
.	O

His	O
prednisone	O
dose	O
was	O
further	O
decreased	O
to	O
5	O
mg	O
/	O
day	O
and	O
mophetil	O
mycophenolate	O
doses	O
sustained	O
.	O

In	O
November	O
2001	O
he	O
developed	O
cutaneous	B-Pathological_formation
purple	I-Pathological_formation
elevated	I-Pathological_formation
lesions	I-Pathological_formation
in	O
his	O
lower	B-Organism_subdivision
limbs	I-Organism_subdivision
that	O
were	O
diagnosed	O
as	O
KS	B-Cancer
by	O
skin	B-Organ
biopsy	O
.	O

He	O
received	O
19	O
administrations	O
of	O
vincristine	O
(	O
1	O
mg	O
)	O
and	O
bleomycin	O
(	O
15	O
mg	O
)	O
weekly	O
that	O
resulted	O
in	O
flattening	O
and	O
fading	O
of	O
the	O
lesions	B-Pathological_formation
.	O

Treatment	O
was	O
discontinued	O
for	O
two	O
months	O
,	O
and	O
KS	B-Cancer
recurred	O
,	O
with	O
pain	O
and	O
edema	B-Pathological_formation
in	O
both	O
legs	B-Organism_subdivision
.	O

On	O
July	O
2002	O
,	O
with	O
an	O
almost	O
100	O
%	O
involvement	O
of	O
his	O
lower	B-Organ
limbs	I-Organ
skin	I-Organ
with	O
KS	B-Cancer
but	O
no	O
visceral	B-Organ
involvement	O
he	O
received	O
50	O
mg	O
of	O
liposomal	O
-	O
adriamycin	O
.	O

In	O
addition	O
,	O
he	O
was	O
then	O
prescribed	O
valganciclovir	O
450	O
mg	O
BID	O
(	O
corrected	O
for	O
creatinine	O
clearance	O
)	O
[	O
7	O
]	O
and	O
three	O
additional	O
administrations	O
of	O
liposomal	O
-	O
adriamycin	O
,	O
up	O
to	O
December	O
2002	O
.	O

He	O
showed	O
40	O
%	O
response	O
again	O
with	O
early	O
relapse	O
.	O

On	O
January	O
2003	O
the	O
patient	O
developed	O
disseminated	O
herpes	O
zoster	O
,	O
which	O
was	O
treated	O
with	O
IV	O
acyclovir	O
.	O

In	O
May	O
2003	O
KS	B-Cancer
progression	O
was	O
observed	O
and	O
received	O
radiotherapy	O
with	O
no	O
benefit	O
Figure	O
1	O
.	O

In	O
August	O
2003	O
he	O
started	O
oral	B-Organism_subdivision
etoposide	O
at	O
50	O
mg	O
QD	O
for	O
two	O
weeks	O
followed	O
by	O
two	O
weeks	O
off	O
until	O
May	O
2004	O
achieving	O
a	O
very	O
slow	O
50	O
%	O
response	O
.	O

Tolerance	O
was	O
good	O
and	O
serum	B-Organism_substance
creatinine	O
remain	O
stable	O
at	O
around	O
1	O
,	O
4	O
mg	O
/	O
dl	O
.	O

Mophetil	O
mycophenolate	O
dose	O
was	O
reduced	O
to	O
1	O
g	O
/	O
day	O
and	O
prednisone	O
to	O
2	O
.	O
5	O
mg	O
/	O
day	O
.	O

Figure	O
1	O

Kaposi	B-Cancer
'	I-Cancer
s	I-Cancer
sarcoma	I-Cancer
progressions	O
after	O
chemotherapy	O
withdrawal	O
,	O
both	O
lower	B-Organism_subdivision
limbs	I-Organism_subdivision
were	O
completely	O
covered	O
with	O
Kaposi	B-Cancer
'	I-Cancer
s	I-Cancer
Sarcoma	I-Cancer
(	O
June	O
2003	O
)	O
.	O

On	O
May	O
2004	O
the	O
patient	O
requested	O
a	O
second	O
opinion	O
and	O
was	O
prescribed	O
Imatinib	O
200	O
mg	O
qd	O
for	O
two	O
weeks	O
followed	O
by	O
400	O
mg	O
qd	O
.	O

After	O
four	O
weeks	O
of	O
Imatinib	O
,	O
his	O
health	O
deteriorated	O
rapidly	O
,	O
he	O
developed	O
anasarca	B-Pathological_formation
,	O
worsening	O
of	O
KS	B-Cancer
,	O
his	O
serum	B-Organism_substance
creatinine	O
increased	O
from	O
1	O
.	O
4	O
mg	O
/	O
dl	O
to	O
2	O
.	O
3	O
mg	O
/	O
dl	O
and	O
he	O
developed	O
grade	O
4	O
granulocytopenia	O
(	O
Figure	O
2	O
)	O
.	O

The	O
patient	O
was	O
hospitalized	O
with	O
fever	O
and	O
was	O
started	O
on	O
IV	O
antibiotics	O
and	O
daily	O
G	O
-	O
CSF	O
for	O
four	O
days	O
after	O
which	O
his	O
WBC	B-Cell
count	O
normalized	O
.	O

Two	O
weeks	O
later	O
the	O
creatinine	O
level	O
returned	O
to	O
1	O
.	O
5	O
mg	O
/	O
dl	O
.	O

On	O
February	O
2005	O
he	O
was	O
started	O
on	O
30	O
mg	O
of	O
paclitaxel	O
IV	O
every	O
three	O
weeks	O
.	O

After	O
three	O
courses	O
with	O
no	O
clinical	O
benefit	O
he	O
developed	O
a	O
skin	B-Organ
rash	O
that	O
prompted	O
discontinuation	O
.	O

Figure	O
2	O

Patient	O
developed	O
anasarca	B-Pathological_formation
with	O
rapid	O
progression	O
of	O
Kaposi	B-Cancer
'	I-Cancer
s	I-Cancer
Sarcoma	I-Cancer
after	O
four	O
weeks	O
of	O
taking	O
Imatinib	O
(	O
June	O
2004	O
)	O
.	O

On	O
April	O
2005	O
,	O
he	O
was	O
started	O
on	O
Sirolimus	O
2	O
mg	O
a	O
day	O
,	O
and	O
after	O
8	O
weeks	O
escalated	O
to	O
4	O
mg	O
a	O
day	O
.	O

Three	O
weeks	O
later	O
mophetil	O
mycophenolate	O
and	O
prednisone	O
were	O
discontinued	O
.	O

Sustained	O
and	O
significant	O
KS	B-Cancer
regression	O
was	O
evident	O
after	O
16	O
weeks	O
,	O
but	O
he	O
developed	O
a	O
basal	B-Cancer
cell	I-Cancer
carcinoma	I-Cancer
and	O
pneumonia	O
that	O
required	O
hospital	O
admission	O
;	O
Sirolimus	O
dose	O
was	O
lowered	O
to	O
2	O
mg	O
a	O
day	O
.	O

Thereafter	O
his	O
clinical	O
course	O
has	O
been	O
satisfactory	O
with	O
continuous	O
and	O
progressive	O
regression	O
of	O
KS	B-Cancer
lesions	I-Cancer
(	O
Figure	O
3	O
)	O
.	O

His	O
serum	B-Organism_substance
creatinine	O
has	O
remained	O
under	O
1	O
.	O
6	O
mg	O
/	O
dl	O
and	O
he	O
has	O
not	O
developed	O
new	O
infectious	O
episodes	O
.	O

Figure	O
3	O

Extensive	O
regression	O
of	O
Kaposi	B-Cancer
Sarcoma	I-Cancer
after	O
immune	O
-	O
suppression	O
was	O
changed	O
to	O
Sirolimus	O
,	O
(	O
14	O
months	O
later	O
)	O
,	O
he	O
only	O
has	O
hyperpigmented	O
areas	O
at	O
knee	B-Organism_subdivision
levels	O
,	O
skin	B-Organ
looks	O
thin	O
and	O
delicate	O
and	O
easily	O
bruised	O
(	O
July	O
2006	O
)	O
.	O

